FUBIMINA
FUBIMINA is a synthetic cannabinoid that is the benzimidazole analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM.
FUBIMINA acts as a reasonably potent agonist for the CB2 receptor, with 12x selectivity over CB1, and does not fully substitute for Δ9-THC in rat discrimination studies.
Related benzimidazole derivatives have been reported to be highly selective agonists for the CB2 receptor.
